Amylyx Pharmaceuticals has reported the data behind a Phase III trial win for its investigational glucagon-like peptide-1 (GLP-1) receptor antagonist in post-bariatric hypoglycaemia (PBH).
The randomised, double-blind, multicentre, placebo-controlled LUCIDITY study (NCT06747468) assessed the safety and efficacy of avexitide in 78 adult patients who developed PBH following Roux-en-Y gastric bypass (RYGB) surgery.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Across 21 US sites, patients completed an initial screening period of up to six weeks, including a three-week run-in phase, before being randomised 3:2 to receive either 90mg avexitide or placebo.
Patients received standard-of-care (SOC) dietary management throughout the run-in period and the 16-week double-blind treatment phase, after which all eligible patients entered a 32-week open-label extension.
Over the 16-week blinded phase, once-daily subcutaneous avexitide reduced the composite rate of self-monitoring of blood glucose-confirmed Level 2 and blinded Event Adjudication Committee-adjudicated Level 3 hypoglycaemic events by 55% compared with placebo.
The least squares (LS) mean event rate reached 0.55 events per week with avexitide versus 1.24 events per week with placebo, achieving statistical significance.
The study met all prespecified, multiplicity-controlled secondary event-rate endpoints, cutting Level 2 events by 63%, Level 3 events by 47%, and continuous glucose monitoring-detected Level 2 events by 42%.
In a secondary within-arm analysis, hypoglycaemic events fell by 72.9% in the avexitide cohort, compared with a 37.8% decrease in the placebo group.
Baseline disease burden was high, with 68% reporting daily hypoglycaemic symptoms, 47% having a history of loss of consciousness, and 28% having previous hospital admissions related to hypoglycaemia.
Completion rates exceeded 90% during the double-blind phase, with 45 of 47 patients completing therapy in the avexitide arm and 28 of 31 participants finishing in the placebo group.
Treatment-emergent adverse events (AEs) were primarily gastrointestinal and injection-site related, generally mild to moderate, with no deaths, no treatment-related serious adverse events, and no clinically meaningful changes in weight or fasting glucose.
Amylyx chief medical officer Camille Bedrosian said: “The presentation of our Phase III LUCIDITY results represents a pivotal milestone in our work to address the longstanding treatment gap for people living with PBH.
“The results shared today reinforce the consistency and strength of the data, with avexitide demonstrating highly statistically significant and clinically meaningful reductions in hypoglycemic events across all prespecified endpoints.
“These positive data, together with positive results from five prior trials of avexitide in PBH, support the potential for avexitide to change practice for this debilitating condition.”
The US Food and Drug Administration (FDA) has previously granted breakthrough therapy designation to avexitide for PBH, alongside orphan drug designation (ODD) for the treatment of hyperinsulinemic hypoglycemia.
Amylyx Pharmaceuticals acquired the drug through a $35m investment in Eiger BioPharmaceuticals.
